Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm
Open Access
- 1 January 2006
- journal article
- research article
- Published by Elsevier in Laboratory Investigation
- Vol. 19 (4), 481-487
- https://doi.org/10.1038/modpathol.3800555
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibilityLaboratory Investigation, 2005
- Targeted Therapy in Breast CancerMolecular & Cellular Proteomics, 2004
- Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcomeLaboratory Investigation, 2004
- Determination of HER-2 Status and Chromosome 17 Polysomy in Breast Carcinomas Comparing HercepTest and PathVysion FISH AssayAmerican Journal of Clinical Pathology, 2004
- Current Perspectives on HER2 Testing: A Review of National Testing GuidelinesLaboratory Investigation, 2003
- Determination of HER2 Gene Amplification by Chromogenic In Situ Hybridization (CISH) in Archival Breast CarcinomaLaboratory Investigation, 2002
- Testing for HER2 StatusOncology, 2001
- Chromogenic in Situ HybridizationThe American Journal of Pathology, 2000
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987